Amryt Pharma, a biopharmaceutical company focused on rare and orphan diseases, completed the acquisition of Aegerion Therapeutics, a biopharmaceutical company, from Novelion Therapeutics, a biopharmaceutical company, for $400m. "The acquisition of Aegerion accelerates our ambition to become a global leader in treating rare conditions to help improve the lives of patients where there is a high unmet medical need. By delivering two substantial revenue-generating products and an enhanced pipeline of promising development opportunities, this will significantly strengthen our growth in highly attractive markets globally. Amryt has a unique insight into both Aegerion and its products, through our commercial success with Lojuxta® and given that many of our senior management team previously worked at Aegerion," Joe Wiley, Amryt Chief Executive Officer.